ArticleFrontiers in oncology2022
Network Pharmacology and Transcriptomic Sequencing Analyses Reveal the Molecular Mechanism of
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Therapeutic Potential of Ziyuglycosides fromDrug design, development and therapy · 2026Review
- Combining Network Pharmacology and Transcriptomic Strategies to Explore the Pharmacological Mechanism of Total Ginsenoside Ginseng Root and Its Impact on Antidepressant Effects.International journal of molecular sciences · 2024Article
- Chemical component of differences in the endosperm ofFood chemistry: X · 2024Article
- Article
- Prognosis and Novel Drug Targets for Key lncRNAs of Epigenetic Modification in Colorectal Cancer.Mediators of inflammation · 2023Article
- Liquid chromatography-tandem mass spectrometry analysis of a ratio-optimized drug pair ofFrontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is the most common malignant cancer worldwide. Method: Firstly, the active ingredients and potential targets of Results: In total, 14 active ingredients and 273 potential targets against CRC were identified in Conclusion: In conclusion, network pharmacology and transcriptomic sequencing analyses, in combination with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.